AngioDynamics (ANGO) Releases FY19 Earnings Guidance

Share on StockTwits

AngioDynamics (NASDAQ:ANGO) updated its FY19 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus estimate of $0.85. The company issued revenue guidance of $348-353 million, compared to the consensus revenue estimate of $345.19 million.

Several research firms recently commented on ANGO. BidaskClub downgraded AngioDynamics from a strong-buy rating to a buy rating in a research report on Thursday, August 30th. Zacks Investment Research downgraded AngioDynamics from a buy rating to a hold rating in a research report on Tuesday, June 5th. Canaccord Genuity restated a hold rating and set a $20.00 target price on shares of AngioDynamics in a research report on Thursday, July 12th. Finally, Raymond James downgraded AngioDynamics from an outperform rating to a market perform rating in a research report on Wednesday, July 11th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $18.44.

AngioDynamics stock opened at $22.96 on Thursday. The company has a quick ratio of 2.08, a current ratio of 2.93 and a debt-to-equity ratio of 0.16. The company has a market cap of $831.23 million, a P/E ratio of 31.03 and a beta of 0.93. AngioDynamics has a one year low of $15.16 and a one year high of $23.95.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, July 11th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01). AngioDynamics had a net margin of 4.74% and a return on equity of 5.21%. The business had revenue of $88.30 million during the quarter, compared to the consensus estimate of $89.02 million. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. equities research analysts forecast that AngioDynamics will post 0.86 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: Closed-End Mutual Funds (CEFs)

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.

Leave a Reply